857 related articles for article (PubMed ID: 29213270)
1. Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
Bannas P; Hambach J; Koch-Nolte F
Front Immunol; 2017; 8():1603. PubMed ID: 29213270
[TBL] [Abstract][Full Text] [Related]
2. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
Front Immunol; 2018; 9():2553. PubMed ID: 30524421
[TBL] [Abstract][Full Text] [Related]
3. Development of Antibody and Nanobody Tools for P2X7.
Stähler T; Danquah W; Demeules M; Gondé H; Hardet R; Haag F; Adriouch S; Koch-Nolte F; Menzel S
Methods Mol Biol; 2022; 2510():99-127. PubMed ID: 35776322
[TBL] [Abstract][Full Text] [Related]
4. Nanobodies as efficient drug-carriers: Progress and trends in chemotherapy.
Panikar SS; Banu N; Haramati J; Del Toro-Arreola S; Riera Leal A; Salas P
J Control Release; 2021 Jun; 334():389-412. PubMed ID: 33964364
[TBL] [Abstract][Full Text] [Related]
5. Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma.
Bannas P; Koch-Nolte F
Front Immunol; 2018; 9():2559. PubMed ID: 30459772
[TBL] [Abstract][Full Text] [Related]
6. Fully synthetic platform to rapidly generate tetravalent bispecific nanobody-based immunoglobulins.
Misson Mindrebo L; Liu H; Ozorowski G; Tran Q; Woehl J; Khalek I; Smith JM; Barman S; Zhao F; Keating C; Limbo O; Verma M; Liu J; Stanfield RL; Zhu X; Turner HL; Sok D; Huang PS; Burton DR; Ward AB; Wilson IA; Jardine JG
Proc Natl Acad Sci U S A; 2023 Jun; 120(24):e2216612120. PubMed ID: 37276407
[TBL] [Abstract][Full Text] [Related]
7. High-expression of monoclonal nanobodies used in the preparation of HRP-conjugated second antibody.
Ahmadvand D; Rahbarizadeh F; Vishteh VK
Hybridoma (Larchmt); 2008 Aug; 27(4):269-76. PubMed ID: 18707545
[TBL] [Abstract][Full Text] [Related]
8. Nanobodies: The Future of Antibody-Based Immune Therapeutics.
Bathula NV; Bommadevara H; Hayes JM
Cancer Biother Radiopharm; 2021 Mar; 36(2):109-122. PubMed ID: 32936001
[TBL] [Abstract][Full Text] [Related]
9. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
10. Introduction to heavy chain antibodies and derived Nanobodies.
Vincke C; Muyldermans S
Methods Mol Biol; 2012; 911():15-26. PubMed ID: 22886243
[TBL] [Abstract][Full Text] [Related]
11. In vivo near-infrared fluorescence targeting of T cells: comparison of nanobodies and conventional monoclonal antibodies.
Bannas P; Well L; Lenz A; Rissiek B; Haag F; Schmid J; Hochgräfe K; Trepel M; Adam G; Ittrich H; Koch-Nolte F
Contrast Media Mol Imaging; 2014; 9(2):135-42. PubMed ID: 24523058
[TBL] [Abstract][Full Text] [Related]
12. Applications of nanobodies in plant science and biotechnology.
Wang W; Yuan J; Jiang C
Plant Mol Biol; 2021 Jan; 105(1-2):43-53. PubMed ID: 33037986
[TBL] [Abstract][Full Text] [Related]
13. [Single-domain antibody - advances in research and application].
Kang X; Cao J; Zhang B; Yuan Q
Sheng Wu Gong Cheng Xue Bao; 2018 Dec; 34(12):1974-1984. PubMed ID: 30584708
[TBL] [Abstract][Full Text] [Related]
14. Application Progress of the Single Domain Antibody in Medicine.
Tang H; Gao Y; Han J
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835588
[TBL] [Abstract][Full Text] [Related]
15. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
16. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
Schriewer L; Schütze K; Petry K; Hambach J; Fumey W; Koenigsdorf J; Baum N; Menzel S; Rissiek B; Riecken K; Fehse B; Röckendorf JL; Schmid J; Albrecht B; Pinnschmidt H; Ayuk F; Kröger N; Binder M; Schuch G; Hansen T; Haag F; Adam G; Koch-Nolte F; Bannas P
Theranostics; 2020; 10(6):2645-2658. PubMed ID: 32194826
[No Abstract] [Full Text] [Related]
17. NANOBODIES®: A Review of Diagnostic and Therapeutic Applications.
Jin BK; Odongo S; Radwanska M; Magez S
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983063
[TBL] [Abstract][Full Text] [Related]
18. Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions.
Nichols P; Li L; Kumar S; Buck PM; Singh SK; Goswami S; Balthazor B; Conley TR; Sek D; Allen MJ
MAbs; 2015; 7(1):212-30. PubMed ID: 25559441
[TBL] [Abstract][Full Text] [Related]
19. Targeting tumors with nanobodies for cancer imaging and therapy.
Oliveira S; Heukers R; Sornkom J; Kok RJ; van Bergen En Henegouwen PM
J Control Release; 2013 Dec; 172(3):607-17. PubMed ID: 24035975
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
